AEGIS BIO named a laureate of the i-Lab 2026 Innovation Competition
AEGIS BIO is proud to announce that it has been selected as a laureate of the 2026 i-Lab Innovation Competition, a flagship national program supporting high-potential deep-tech companies, operated by Bpifrance on behalf of the French State.
This highly competitive recognition marks a major milestone for AEGIS BIO and validates the scientific, technological, and translational potential of our approach. The support provided through i-Lab and Bpifrance will help accelerate the preclinical development of our lead program and strengthen its path toward clinical translation.
Our ambition is clear: to develop a new generation of protective therapies that can be administered alongside essential treatments such as chemotherapy, helping shield healthy organs from severe and potentially irreversible toxicities, particularly in vulnerable patient populations, including children with cancer.
For AEGIS BIO, this award represents both a recognition of the progress achieved and a powerful catalyst for the next phase of our journey toward the clinic.